Press releaseGlobe Newswire
Marinus Pharmaceuticals
MRNS · NASDAQ
Price unavailable right now.
No price history for this range.
Latest news
- Press releaseGlobe Newswire
MARINUS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Marinus Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPY, HEES, MRNS on Behalf of Shareholders
- Press releasePRNewswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AE, MRNS, SASR, ROIC to Take Action
- Press releasePRNewswire
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MRNS, RHE, SSY, CTV on Behalf of Shareholders
- Press releaseBusiness Wire
MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OMIC, MRNS, VCSA, LBRDA on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders
- Press releaseBusiness Wire
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
- Press releaseBusiness Wire
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
- News
Immedica Pharma to Acquire Marinus Pharmaceuticals in Strategic Merger For $0.55/Share Implying An Enterprise Value Of $151M
- Press releaseBusiness Wire
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
- Press releaseBusiness Wire
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsVandana Singh
Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
- NewsAvi Kapoor
Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
- NewsAvi Kapoor
Dow Falls 150 Points; Tesla Posts Upbeat Earnings
- News
Marinus Pharmaceuticals Shares Halted Pending News
- Press releaseBusiness Wire
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
- Press releaseBusiness Wire
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
- Press releaseBusiness Wire
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
- Press releaseBusiness Wire
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
- Press releaseBusiness Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Press releaseBusiness Wire
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
- Press releaseBusiness Wire
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
- Press releaseBusiness Wire
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
- Press releaseBusiness Wire
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
- Press releaseBusiness Wire
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
- Press releaseBusiness Wire
Ligand Reports Second Quarter 2024 Financial Results
- Press releaseNewsfile
MRNS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm
- Press releaseBusiness Wire
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.